Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer
Zhiyong Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), J. Silvio Gutkind(National Institutes of Health), Mara Gilardi(Champions Oncology (United States)), Bryan S. Yung(City Of Hope National Medical Center), Joseph A. Califano(University of California San Diego), Aoife O’Farrell(University of California San Diego), Diego Alvarado(Unknown), Ezra E.W. Cohen(Moores Cancer Center), Michael M. Allevato(University of California San Diego), Umamaheswar Duvvuri(City University of New York), Alfredo Molinolo(University of San Diego), Yusuke Goto(Chiba University), Jennifer R. Grandis(University of California, San Francisco), Victoria H. Wu(University of California San Diego), Robert Saddawi‐Konefka(The University of Texas MD Anderson Cancer Center)
Cited by 86
Related Papers
Head and neck squamous cell carcinoma
|Nature Reviews Disease Primers|2020|4k
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
|Immunity|2020|688